Evaluation of encapsulated Newcastle disease virus liposomes using various phospholipids administered to improve chicken humoral immunity

Li Ping Tseng, Chwei Jang Chiou, Ming Chung Deng, Mei Hsiu Lin, Ryh Nan Pan, Yi You Huang, Der Zen Liu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We propose the adjuvant effects of phospholipid liposome compositions using intranasal inoculation of a liposomal-Newcastle disease virus (NDV) vaccine in chickens. The immunogenicity of three liposome formulations was determined in chickens using the hemagglutination-inhibition (HI) test, nasal secretory immunoglobulin A and serum immunoglobulin A (IgG) antibody titers using the enzyme-linked immunosorbent assay. The immune response against NDV antigens was determined after immunization with neutral charged liposomes composed of egg phosphatidylcholine (EPC) (60 μmol), cholesterol (Chol) (15 μmol), and EPC-liposomes (EPC-Lip), which elicited strong systemic (serum) and local (nasal) humoral responses. However, the intranasal administration with cationic charged liposomes composed of EPC (30 μmol), stearylamine (SA) (15 μmol), Chol (15 μmol), and SA-liposomes (SA-Lip) induced poor humoral immune responses. Only the vaccine formulated with anionic charged liposomes composed of EPC (30 μmol), dipalmitoylphosphatidylserine (15 μmol), Chol (15 μmol), and phosphatidylserine-liposomes (PS-Lip) elicited the highest titers of HI antibodies. These are the first results to suggest that antigen delivery using EPCLip is very useful in enhancing antibody production at the mucosal site and in serum.

Original languageEnglish
Pages (from-to)621-625
Number of pages5
JournalJournal of Biomedical Materials Research - Part B Applied Biomaterials
Volume91
Issue number2
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Liposomes
Phospholipids
Viruses
Phosphatidylcholines
Cholesterol
Antibodies
Vaccines
Antigens
Immunization
Secretory Immunoglobulin A
Immunosorbents
Blocking Antibodies
Phosphatidylserines
Immunoglobulin A
Assays
Enzymes
Immunoglobulin G
Chemical analysis

Keywords

  • Adjuvant
  • Intranasal delivery
  • Liposomal vaccine
  • Newcastle disease virus

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials

Cite this

Evaluation of encapsulated Newcastle disease virus liposomes using various phospholipids administered to improve chicken humoral immunity. / Tseng, Li Ping; Chiou, Chwei Jang; Deng, Ming Chung; Lin, Mei Hsiu; Pan, Ryh Nan; Huang, Yi You; Liu, Der Zen.

In: Journal of Biomedical Materials Research - Part B Applied Biomaterials, Vol. 91, No. 2, 11.2009, p. 621-625.

Research output: Contribution to journalArticle

@article{30a9805493cc4fd8809613a809f37cd5,
title = "Evaluation of encapsulated Newcastle disease virus liposomes using various phospholipids administered to improve chicken humoral immunity",
abstract = "We propose the adjuvant effects of phospholipid liposome compositions using intranasal inoculation of a liposomal-Newcastle disease virus (NDV) vaccine in chickens. The immunogenicity of three liposome formulations was determined in chickens using the hemagglutination-inhibition (HI) test, nasal secretory immunoglobulin A and serum immunoglobulin A (IgG) antibody titers using the enzyme-linked immunosorbent assay. The immune response against NDV antigens was determined after immunization with neutral charged liposomes composed of egg phosphatidylcholine (EPC) (60 μmol), cholesterol (Chol) (15 μmol), and EPC-liposomes (EPC-Lip), which elicited strong systemic (serum) and local (nasal) humoral responses. However, the intranasal administration with cationic charged liposomes composed of EPC (30 μmol), stearylamine (SA) (15 μmol), Chol (15 μmol), and SA-liposomes (SA-Lip) induced poor humoral immune responses. Only the vaccine formulated with anionic charged liposomes composed of EPC (30 μmol), dipalmitoylphosphatidylserine (15 μmol), Chol (15 μmol), and phosphatidylserine-liposomes (PS-Lip) elicited the highest titers of HI antibodies. These are the first results to suggest that antigen delivery using EPCLip is very useful in enhancing antibody production at the mucosal site and in serum.",
keywords = "Adjuvant, Intranasal delivery, Liposomal vaccine, Newcastle disease virus",
author = "Tseng, {Li Ping} and Chiou, {Chwei Jang} and Deng, {Ming Chung} and Lin, {Mei Hsiu} and Pan, {Ryh Nan} and Huang, {Yi You} and Liu, {Der Zen}",
year = "2009",
month = "11",
doi = "10.1002/jbm.b.31437",
language = "English",
volume = "91",
pages = "621--625",
journal = "Journal of Biomedical Materials Research - Part B Applied Biomaterials",
issn = "1552-4973",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Evaluation of encapsulated Newcastle disease virus liposomes using various phospholipids administered to improve chicken humoral immunity

AU - Tseng, Li Ping

AU - Chiou, Chwei Jang

AU - Deng, Ming Chung

AU - Lin, Mei Hsiu

AU - Pan, Ryh Nan

AU - Huang, Yi You

AU - Liu, Der Zen

PY - 2009/11

Y1 - 2009/11

N2 - We propose the adjuvant effects of phospholipid liposome compositions using intranasal inoculation of a liposomal-Newcastle disease virus (NDV) vaccine in chickens. The immunogenicity of three liposome formulations was determined in chickens using the hemagglutination-inhibition (HI) test, nasal secretory immunoglobulin A and serum immunoglobulin A (IgG) antibody titers using the enzyme-linked immunosorbent assay. The immune response against NDV antigens was determined after immunization with neutral charged liposomes composed of egg phosphatidylcholine (EPC) (60 μmol), cholesterol (Chol) (15 μmol), and EPC-liposomes (EPC-Lip), which elicited strong systemic (serum) and local (nasal) humoral responses. However, the intranasal administration with cationic charged liposomes composed of EPC (30 μmol), stearylamine (SA) (15 μmol), Chol (15 μmol), and SA-liposomes (SA-Lip) induced poor humoral immune responses. Only the vaccine formulated with anionic charged liposomes composed of EPC (30 μmol), dipalmitoylphosphatidylserine (15 μmol), Chol (15 μmol), and phosphatidylserine-liposomes (PS-Lip) elicited the highest titers of HI antibodies. These are the first results to suggest that antigen delivery using EPCLip is very useful in enhancing antibody production at the mucosal site and in serum.

AB - We propose the adjuvant effects of phospholipid liposome compositions using intranasal inoculation of a liposomal-Newcastle disease virus (NDV) vaccine in chickens. The immunogenicity of three liposome formulations was determined in chickens using the hemagglutination-inhibition (HI) test, nasal secretory immunoglobulin A and serum immunoglobulin A (IgG) antibody titers using the enzyme-linked immunosorbent assay. The immune response against NDV antigens was determined after immunization with neutral charged liposomes composed of egg phosphatidylcholine (EPC) (60 μmol), cholesterol (Chol) (15 μmol), and EPC-liposomes (EPC-Lip), which elicited strong systemic (serum) and local (nasal) humoral responses. However, the intranasal administration with cationic charged liposomes composed of EPC (30 μmol), stearylamine (SA) (15 μmol), Chol (15 μmol), and SA-liposomes (SA-Lip) induced poor humoral immune responses. Only the vaccine formulated with anionic charged liposomes composed of EPC (30 μmol), dipalmitoylphosphatidylserine (15 μmol), Chol (15 μmol), and phosphatidylserine-liposomes (PS-Lip) elicited the highest titers of HI antibodies. These are the first results to suggest that antigen delivery using EPCLip is very useful in enhancing antibody production at the mucosal site and in serum.

KW - Adjuvant

KW - Intranasal delivery

KW - Liposomal vaccine

KW - Newcastle disease virus

UR - http://www.scopus.com/inward/record.url?scp=71649100288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71649100288&partnerID=8YFLogxK

U2 - 10.1002/jbm.b.31437

DO - 10.1002/jbm.b.31437

M3 - Article

C2 - 19582853

AN - SCOPUS:71649100288

VL - 91

SP - 621

EP - 625

JO - Journal of Biomedical Materials Research - Part B Applied Biomaterials

JF - Journal of Biomedical Materials Research - Part B Applied Biomaterials

SN - 1552-4973

IS - 2

ER -